Table of Contents

Chapter 1 Overview of Kidney/Renal Fibrosis Treatment

• 1.1 Definition of Kidney/Renal Fibrosis Treatment in This Report
• 1.2 Commercial Types of Kidney/Renal Fibrosis Treatment
  • 1.2.1 Angiotensin II Receptor Blockers (ARBs)
  • 1.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors
  • 1.2.3 Pirfenidone
  • 1.2.4 Renin Inhibitors
  • 1.2.5 Vasopeptidase Inhibitors
• 1.3 Downstream Application of Kidney/Renal Fibrosis Treatment
  • 1.3.1 Commercial/Private Hospitals
  • 1.3.2 Public Health Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Home Treatment
• 1.4 Development History of Kidney/Renal Fibrosis Treatment
• 1.5 Market Status and Trend of Kidney/Renal Fibrosis Treatment 2013-2023
  • 1.5.1 Global Kidney/Renal Fibrosis Treatment Market Status and Trend 2013-2023
  • 1.5.2 Regional Kidney/Renal Fibrosis Treatment Market Status and Trend 2013-2023

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Kidney/Renal Fibrosis Treatment 2013-2017
• 2.2 Production Market of Kidney/Renal Fibrosis Treatment by Regions
  • 2.2.1 Production Volume of Kidney/Renal Fibrosis Treatment by Regions
  • 2.2.2 Production Value of Kidney/Renal Fibrosis Treatment by Regions
• 2.3 Demand Market of Kidney/Renal Fibrosis Treatment by Regions
• 2.4 Production and Demand Status of Kidney/Renal Fibrosis Treatment by Regions
  • 2.4.1 Production and Demand Status of Kidney/Renal Fibrosis Treatment by Regions 2013-2017
  • 2.4.2 Import and Export Status of Kidney/Renal Fibrosis Treatment by Regions 2013-2017

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Kidney/Renal Fibrosis Treatment by Types
• 3.2 Production Value of Kidney/Renal Fibrosis Treatment by Types
• 3.3 Market Forecast of Kidney/Renal Fibrosis Treatment by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Kidney/Renal Fibrosis Treatment by Downstream Industry
• 4.2 Market Forecast of Kidney/Renal Fibrosis Treatment by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Kidney/Renal Fibrosis Treatment

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Kidney/Renal Fibrosis Treatment Downstream Industry Situation and Trend Overview

Chapter 6 Kidney/Renal Fibrosis Treatment Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Kidney/Renal Fibrosis Treatment by Major Manufacturers
• 6.2 Production Value of Kidney/Renal Fibrosis Treatment by Major Manufacturers
• 6.3 Basic Information of Kidney/Renal Fibrosis Treatment by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Kidney/Renal Fibrosis Treatment Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Kidney/Renal Fibrosis Treatment Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Kidney/Renal Fibrosis Treatment Major Manufacturers Introduction and Market Data

• 7.1 La Jolla Pharmaceutical Company
  • 7.1.1 Company profile
  • 7.1.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.1.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of La Jolla Pharmaceutical Company
• 7.2 Genzyme Corporation
  • 7.2.1 Company profile
  • 7.2.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.2.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of Genzyme Corporation
• 7.3 Pfizer Inc.
  • 7.3.1 Company profile
  • 7.3.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.3.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of Pfizer Inc.
• 7.4 Merck & Co.
  • 7.4.1 Company profile
  • 7.4.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.4.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of Merck & Co.
• 7.5 Galectin Therapeutics
  • 7.5.1 Company profile
  • 7.5.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.5.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of Galectin Therapeutics
• 7.6 F. Hoffman-La Roche Ltd.
  • 7.6.1 Company profile
  • 7.6.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.6.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of F. Hoffman-La Roche Ltd.
• 7.7 ProMetic Life-Sciences Inc.
  • 7.7.1 Company profile
  • 7.7.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.7.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of ProMetic Life-Sciences Inc.
• 7.8 InterMune Inc.
  • 7.8.1 Company profile
  • 7.8.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.8.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of InterMune Inc.
• 7.9 BioLine Rx Ltd
  • 7.9.1 Company profile
  • 7.9.2 Representative Kidney/Renal Fibrosis Treatment Product
  • 7.9.3 Kidney/Renal Fibrosis Treatment Sales, Revenue, Price and Gross Margin of BioLine Rx Ltd

Chapter 8 Upstream and Downstream Market Analysis of Kidney/Renal Fibrosis Treatment

• 8.1 Industry Chain of Kidney/Renal Fibrosis Treatment
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Kidney/Renal Fibrosis Treatment

• 9.1 Cost Structure Analysis of Kidney/Renal Fibrosis Treatment
• 9.2 Raw Materials Cost Analysis of Kidney/Renal Fibrosis Treatment
• 9.3 Labor Cost Analysis of Kidney/Renal Fibrosis Treatment
• 9.4 Manufacturing Expenses Analysis of Kidney/Renal Fibrosis Treatment

Chapter 10 Marketing Status Analysis of Kidney/Renal Fibrosis Treatment

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources

Report Summary

Kidney/Renal Fibrosis Treatment-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Kidney/Renal Fibrosis Treatment industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Kidney/Renal Fibrosis Treatment 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Kidney/Renal Fibrosis Treatment worldwide, with company and product introduction, position in the Kidney/Renal Fibrosis Treatment market
Market status and development trend of Kidney/Renal Fibrosis Treatment by types and applications
Cost and profit status of Kidney/Renal Fibrosis Treatment, and marketing status
Market growth drivers and challenges

The report segments the global Kidney/Renal Fibrosis Treatment market as:

Global Kidney/Renal Fibrosis Treatment Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America

Global Kidney/Renal Fibrosis Treatment Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Angiotensin II Receptor Blockers (ARBs)
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Vasopeptidase Inhibitors

Global Kidney/Renal Fibrosis Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Commercial/Private Hospitals
Public Health Hospitals
Clinics
Home Treatment

Global Kidney/Renal Fibrosis Treatment Market: Manufacturers Segment Analysis (Company and Product introduction, Kidney/Renal Fibrosis Treatment Sales Volume, Revenue, Price and Gross Margin):
La Jolla Pharmaceutical Company
Genzyme Corporation
Pfizer Inc.
Merck & Co.
Galectin Therapeutics
F. Hoffman-La Roche Ltd.
ProMetic Life-Sciences Inc.
InterMune Inc.
BioLine Rx Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.